Application route and immune status of the host determine safety and oncolytic activity of oncolytic coxsackievirus b3 variant pd-h

HIGHLIGHTS

• who: Ahmet Hazini and colleagues from the Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, Department of Oncology, University of Oxford, Oxford , DQ, UK have published the article: Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H, in the Journal: Viruses 2021, 13, 1918. of /2021/
• what: The authors show that PD-H has similar functionality as PD-0 in_vitro. The authors show that virus-induced side effects in_vivo can be prevented by insertion of miR-TS of the miR-375 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.